Analysis of drug-sensitivity data of ∼500 solid tumor cancer cell lines from a high-throughput drug screen (Garnett et al., 2012) indicated that among all solid tumor types, neuroblastoma cell lines were exquisitely sensitive to the in-clinic BCL-2/BCL-2/xL inhibitor ABT-263 (navitoclax) (Figure 1A). This evidence concerns the gene BCL2 and neuroblastoma.